Navigation Links
Graham Cooper Appointed Chief Financial Officer of Receptos

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that Graham Cooper has been appointed Chief Financial Officer. Mr. Cooper joins the company after serving as Chief Financial Officer of Geron Corporation and Orexigen Therapeutics, Inc.

"Graham brings to Receptos tremendous strategic insight and financial experience, including Orexigen's successful initial public offering," said Faheem Hasnain , President and Chief Executive Officer of Receptos. "Graham will play a key leadership role as we capitalize Receptos to execute on our clinical development strategy. He joins us at a particularly exciting time, having initiated the Phase 2 portion of our randomized Phase 2/3 study for RPC1063, which has the potential to be the next S1P1R modulator to market in relapsing multiple sclerosis."

Added Mr. Cooper, "I see a great deal of promise in Receptos' pipeline of therapeutics as well as its skilled leadership team. Receptos is a fast-moving company with a history of strong execution, and I look forward to our evolution into a late-stage clinical development organization."

Cooper joins Receptos from Geron, where he served as EVP-Finance and Chief Financial Officer. In this capacity, he led investor relations and financial activities and served on the Executive Management Committee that oversaw clinical, research, regulatory and financial activities. Prior to Geron, he served as SVP-Finance and Chief Financial Officer of Orexigen from 2006 to 2012. During his tenure, Orexigen raised over $300 million in public and private equity, including $80 million through an initial public offering. Earlier in his career, he served as Director of healthcare banking for Deutsche Bank and as a Senior Accountant for Deloitte & Touche, where he earned his CPA. He received a Master's degree in Business Administration from the Graduate School of Business at Stanford University and a Bachelor's degree in Economics from the University of California, Berkeley.

About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The company's lead program, RPC1063, is a potential best-in-class sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Receptos is currently enrolling patients into the randomized Phase 2 portion of a Phase 2/3 study examining the efficacy of RPC1063 in RMS and a randomized Phase 2 study examining the efficacy of RPC1063 in ulcerative colitis (UC). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs). This expertise has formed the basis of collaborations with Eli Lilly and Ono Pharmaceutical and a partnership with Janssen Pharmaceuticals, Inc. For more information visit

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271

SOURCE Receptos, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
3. Prairie Education & Research Cooperative Joins MedNet Solutions iMedNet CRO Partner Program
4. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
5. CooperVision Renews Its Support of U.S. Military Personnel
6. Herb Baer Appointed President of Polar USA
7. New Executive Vice President Commercial Appointed
8. Israel Makov Appointed Chairman of Sun Pharma Board
9. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
10. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), a ... Executive Officer Antonius Schuh, Ph.D., is scheduled to present ... Piper Jaffray Healthcare Conference. th Annual ... Hotel in New York on ... Schuh will be available for one-on-one meetings during the ...
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, ... friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, ... , For 65 years, Brillianteen has been a treasured tradition for numerous families ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center for Eating ... disorders as a result of the $20,000 raised at the center’s recent ... Golf Club in Eureka, will help individuals who otherwise might not seek treatment ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):